China Traditional Chinese Medicine Holdings Co. Limited has announced that the National Medical Products Administration (NMPA) of China has accepted the new drug application for Yushuda Tablets, a Class 1.1 innovative traditional Chinese medicine developed by its subsidiary, Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd. The acceptance marks the start of a series of regulatory review procedures, including technical evaluation and on-site inspection. Yushuda Tablets have shown significant efficacy in treating symptoms associated with qi stagnation and mild-to-moderate depression. While this is a promising development, the timeline for final approval remains uncertain, and shareholders are advised to exercise caution.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.